Vigil Neuro
Jessica Stromme is an experienced professional in program leadership and portfolio management, currently serving as Senior Vice President at Vigil Neuroscience since February 2021. Prior roles include Vice President of Program Management at Karuna Therapeutics and Executive Director of Program Management at both Ra Pharmaceuticals and Karuna Therapeutics. Jessica has also held managerial positions at Momenta Pharmaceuticals and Good Start Genetics, and began a career in project management at Sarepta Therapeutics. Jessica holds a Bachelor's degree in Chemistry from Oregon State University.
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.